AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for ATP-dependent RNA helicase TDRD9

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NDG6

UPID:

TDRD9_HUMAN

Alternative names:

Tudor domain-containing protein 9

Alternative UPACC:

Q8NDG6; A1A4S7; Q6ZU54; Q8N7T3; Q8N827; Q8N9V5; Q96AS9

Background:

ATP-dependent RNA helicase TDRD9, also known as Tudor domain-containing protein 9, plays a pivotal role in spermatogenesis. It is essential for repressing transposable elements to maintain germline integrity, acting through the piRNA metabolic process. This process is crucial for the methylation and repression of transposons, with TDRD9 acting as a nuclear effector alongside PIWIL4.

Therapeutic significance:

Spermatogenic failure 30, an autosomal recessive infertility disorder linked to TDRD9, highlights the protein's critical role in human health. Understanding TDRD9's function could pave the way for innovative treatments for infertility disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.